Pharmacogenetic Studies Investigating the Adverse Effects of Antipsychotics

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Psychiatry Investigation

• Publication date

  2007-09-01

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Association study between glutathione S‐transferase GST‐M1, GST‐T1, and GST‐P1 polymorphisms and tardive dyskinesia

  2009cited by this paper
• Lack of association between the −759C/T polymorphism of the 5‐HT2C receptor gene and olanzapine‐induced weight gain among Korean schizophrenic patients

  2008cited by this paper
• Association Study between Antipsychotics- Induced Restless Legs Syndrome and Polymorphisms of Dopamine D1, D2, D3, and D4 Receptor Genes in Schizophrenia

  2008cited by this paper
• Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.

  2008cited by this paper
• Possible association between G-protein β3 subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia

  2007cited by this paper
• Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes.

  2007cited by this paper
• No Association between Dopamine D4 Receptor Gene –521 C/T Polymorphism and Tardive Dyskinesia in Schizophrenia

  2007cited by this paper
• No evidence for an association between G protein β3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia

  2007cited by this paper
• Characteristics and clinical correlates of restless legs syndrome in schizophrenia.

  2007cited by this paper
• Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia

  2007cited by this paper
• -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.

  2007cited by this paper
• Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis.

  2007cited by this paper
• No association between a functional NAD(P)H

  2007cited by this paper
• Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.

  2006cited by this paper
• A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

  2006cited by this paper
• Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate.

  2006cited by this paper
• Epigenetics and twins: three variations on the theme.

  2006cited by this paper
• Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients

  2006cited by this paper
• Weight gain associated with the α2a‐adrenergic receptor −1291 C/G polymorphism and olanzapine treatment

  2006cited by this paper
• Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.

  2006cited by this paper
• Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.

  2006cited by this paper
• Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms

  2006cited by this paper
• Genetic association analysis between a functional NAD(P)H: quinone oxidoreductase (NQO1) gene polymorphism (Pro187Ser) and tardive dyskinesia

  2006cited by this paper
• Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia.

  2006cited by this paper
• Genetic basis of toxic reactions to drugs and chemicals.

  2006cited by this paper
• AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.

  2006cited by this paper
• A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13

  2006cited by this paper
• Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

  2005cited by this paper
• Risperidone plasma levels, clinical response and side–effects

  2005cited by this paper
• II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India.

  2005cited by this paper
• Polymorphic Variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and Dopamine D2 and D3 Receptors and Their Association With Tardive Dyskinesia in Severe Mental Illness

  2005cited by this paper
• Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6

  2005cited by this paper
• Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains

  2005cited by this paper
• The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients

  2005cited by this paper
• Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity.

  2005cited by this paper
• Antipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?

  2005cited by this paper
• Genetics and Epigenetics in Major Psychiatric Disorders

  2005cited by this paper
• Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype.

  2005cited by this paper
• C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population

  2005cited by this paper
• Polymorphism of the adrenergic receptor alpha 2a −1291C>G genetic variation and clozapine-induced weight gain

  2005cited by this paper
• The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.

  2005cited by this paper
• Weight gain associated with the −759C/T polymorphism of the 5HT2C receptor and olanzapine

  2005cited by this paper
• Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

  2005cited by this paper
• Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.

  2005cited by this paper
• Prevalence of restless legs syndrome and associated factors in the Korean adult population: The Korean Health and Genome Study

  2005cited by this paper
• A Novel Brain-Targeted Antioxidant (AD4) Attenuates Haloperidol-Induced Abnormal Movement in Rats:: Implications for Tardive Dyskinesia

  2005cited by this paper
• Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain.

  2005cited by this paper
• Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene.

  2004cited by this paper
• Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia.

  2004cited by this paper
• Six Novel Nonsynonymous CYP1A2 Gene Polymorphisms: Catalytic Activities of the Naturally Occurring Variant Enzymes

  2004cited by this paper
• Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

  2004cited by this paper
• Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population

  2004cited by this paper
• Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment.

  2004cited by this paper
• Atypical Antipsychotics and Metabolic Dysregulation: Evaluating the Risk/Benefit Equation and Improving the Standard of Care

  2004cited by this paper
• Lack of association between the –759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals

  2004cited by this paper
• Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

  2004cited by this paper
• Association Study of Adrenergic β3 Receptor (Trp64Arg) and G-Protein β3 Subunit Gene (C825T) Polymorphisms and Weight Change during Clozapine Treatment

  2004cited by this paper
• Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p.

  2004cited by this paper
• Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia.

  2004cited by this paper
• Nonresponse to Clozapine and Ultrarapid CYP1A2 Activity: Clinical Data and Analysis of CYP1A2 Gene

  2004cited by this paper
• A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses

  2004cited by this paper
• The 14q restless legs syndrome locus in the French Canadian population

  2004cited by this paper
• Impact of Myeloperoxidase and NADPH-Oxidase Polymorphisms in Drug-Induced Agranulocytosis

  2004cited by this paper
• Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.

  2004cited by this paper
• Cytochrome P-450 2D6*10 C188T Polymorphism Is Associated with Antipsychotic-Induced Persistent Tardive Dyskinesia in Chinese Schizophrenic Patients

  2004cited by this paper
• The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.

  2003cited by this paper
• Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene.

  2003cited by this paper
• Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain.

  2003cited by this paper
• NQO2 gene is associated with clozapine-induced agranulocytosis.

  2003cited by this paper
• [Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain].

  2003cited by this paper
• Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia

  2003cited by this paper
• Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia

  2003cited by this paper
• Autosomal dominant restless legs syndrome maps on chromosome 14q.

  2003cited by this paper
• Opposite regulation by typical and atypical anti‐psychotics of ERK1/2, CREB and Elk‐1 phosphorylation in mouse dorsal striatum

  2003cited by this paper
• Evidence for a genetic association between monoamine oxidase A and restless legs syndrome

  2002cited by this paper
• The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism.

  2002cited by this paper
• Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.

  2002cited by this paper
• −759C/genetic variation of 5HT2C receptor and clozapine-induced weight gain

  2002cited by this paper
• CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

  2002cited by this paper
• Antipsychotic medication adherence: is there a difference between typical and atypical agents?

  2002cited by this paper
• -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain.

  2002cited by this paper
• General Summary

  2002cited by this paper
• Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia.

  2002cited by this paper
• Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism

  2002cited by this paper
• Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism.

  2002cited by this paper
• Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

  2001cited by this paper
• Treatment-Resistance to Clozapine in Association With Ultrarapid CYP1A2 Activity and the C → A Polymorphism in Intron 1 of the CYP1A2 Gene: Effect of Grapefruit Juice and Low-Dose Fluvoxamine

  2001cited by this paper
• Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor.

  2001cited by this paper
• Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.

  2001cited by this paper
• Genetic variants of the serotonin system and weight change during clozapine treatment.

  2001cited by this paper
• Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

  2001cited by this paper
• Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

  2001cited by this paper
• Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q.

  2001cited by this paper
• Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample.

  2001cited by this paper
• Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.

  2001cited by this paper
• Dopaminergic neurotransmission and restless legs syndrome: A genetic association analysis

  2001cited by this paper
• Novel histamine H1 gene polymorphism and clozapine-induced weight gain

  2000cited by this paper
• Dopamine D3 receptor variant and tardive dyskinesia

  2000cited by this paper
• Atypical antipsychotics and weightgain — a systematic review

  2000cited by this paper
• Association of the G‐2548A polymorphism in the 5′ region of the LEP gene with overweight

  2000cited by this paper

• The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study

  2025cites this paper
• Penfluridol Induced Extrapyramidal symptoms (EPS): A Case Report

  2017cites this paper
• Prevalence of restless legs syndrome among psychiatric patients who are under antidepressant or antipsychotic monotherapy

  2016cites this paper
• Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.

  2013cites this paper
• Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine

  2009cites this paper
• Val158Met Polymorphism in the Catechol-O-Methyltransferase (COMT) Gene Is Not Associated with Tardive Dyskinesia in Schizophrenia

  2008cites this paper
• No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients.

  2008cites this paper
• Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients.

  2008cites this paper